Hikma Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Hikma Pharmaceuticals
Type Public company (LSEHIK)
Industry Pharmaceutical
Founded 1978
Headquarters London, UK
Key people Samih Darwazah Chairman
Said Darwazah CEO
Products Amoclan
Prograf
Suprax
Revenue US$1,365 million (2013)[1]
Operating income US$413 million (2013)[1]
Net income US$216 million (2013)[1]
Employees circa 6,000 (2012)
Website www.hikma.com

Hikma Pharmaceuticals is a multinational pharmaceutical company based in London, that manufactures branded and non-branded generic and in-licensed pharmaceutical products. It was first listed on the London Stock Exchange in 2005 is now the fourth listed pharmaceutical company on the FTSE 250 Index.[2] In 2013, Hikma delivered 23% group revenue growth [3] and is the largest regional pharmaceutical company in the MENA region.[4] It was founded in Jordan in 1978 by Samih Darwazah.

History[edit]

The Company was founded by Samih Darwazah in 1978 in Amman in Jordan.[5] In August 1996 it became the first Arab company to export pharmaceutical products to the United States.[6] It was first listed on the London Stock Exchange in 2005.[5] Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005[7] and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006.[5] In 2007 the Company went on to buy APM in Jordan,[8] Alkan Pharma in Egypt,APM and Al Jazeera Pharma in Saudi Arabia[8] Thymoorgan in Germany[5] and Ribosepharm in Germany.[5] It also acquired Multi-Source Injectables in the USA in October 2010.[9] In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).[10][11]

In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco.[12] Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma’s second venture in Algeria after Hikma Pharma Algeria.[13]

In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.[14]

Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012.[15] In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market [16]

On May 28, 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.[17]


Operations[edit]

Hikma Pharmaceutical’s operations span over 50 countries with 26 manufacturing plants in 11 countries, and 7 R&D centers.[18] The Company's production facilities are located in the following countries:


Business Segments[edit]

Branded

Hikma’s branded business segment comprises the development and sales of branded generics and in-licensed patented products in the MENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Amoclan, Blopress, Omnicef, Prograf and Suprax.[19]

Injectables

Hikma sells specialized injectable products in the US, Europe and MENA including argatroban, fentanyl, phenylephrine, robaxin and iron gluconate. The company sells 200 products in 379 dosage forms and strengths.[20]

Generics

Hikma’s oral generic products are sold in the US and include such products as amoxicillin, cephalexin, doxycycline, methocarbamol and prednisone.[18]

See also[edit]

References[edit]

  1. ^ a b c Preliminary Results 2013
  2. ^ http://www.hikma.com/en/about-hikma/~/media/Files/H/Hikma/Attachments/pdf/hikma-factsheet-2014.pdf
  3. ^ Hikma Annual Report 2013 page 34 http://www.hikma.com/~/media/Files/H/Hikma/Attachments/pdf/reports/financial-reports/annual-report-2013.pdf
  4. ^ Investors Hikma Pharmaceuticals PLC http://www.hikma.com/en/investors/hikma-at-a-glance.aspx
  5. ^ a b c d e Hikma History
  6. ^ Economy – Sectoral Analysis
  7. ^ Hikma Annual Report 2006 Page 62
  8. ^ a b Hikma Annual Report 2007 Page 15
  9. ^ Hikma Pharma to buy Multi-Source Injectables business of Baxter Healthcare
  10. ^ "Hikma Pharmaceuticals Plc Completes Acquisition of Baxter Healthcare Corporation's Multi-Source Injectables Business". Reuters. Retrieved 3 May 2011. 
  11. ^ "History". Hikma Pharmaceuticals PLC. 
  12. ^ http://www.prnewswire.com/news-releases/hikma-enters-the-moroccan-market-through-the-acquisition-of-639-of-promopharm-and-will-launch-a-mandatory-tender-offer-for-the-remaining-361-130992148.html
  13. ^ Hikma Pharmaceuticals Inaugurates Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria http://www.zawya.com/story/ZAWYA20111018104628/
  14. ^ Hikma Receives Transparency in Governance Award 2011
  15. ^ http://www.pmlive.com/pharma_news/hikma_expands_in_egypt_with_epci_acquisition_458329
  16. ^ Hikma Annual Report 2013 page 23 http://www.hikma.com/~/media/Files/H/Hikma/Attachments/pdf/reports/financial-reports/annual-report-2013.pdf
  17. ^ http://www.reuters.com/article/2014/05/28/hikma-pharma-boehringer-idUSL6N0OE2ZU20140528
  18. ^ a b Hikma Annual Report 2013 page 10 http://www.hikma.com/~/media/Files/H/Hikma/Attachments/pdf/reports/financial-reports/annual-report-2013.pdf
  19. ^ Hikma Annual Report 2013 page 11 http://www.hikma.com/~/media/Files/H/Hikma/Attachments/pdf/reports/financial-reports/annual-report-2013.pdf
  20. ^ Hikma Factsheet 2014 http://www.hikma.com/en/about-hikma/~/media/Files/H/Hikma/Attachments/pdf/hikma-factsheet-2014.pdf

External links[edit]